Melanoma & Skin Cancer Articles | Page 3

Novel Combinations Mark Next Step for Melanoma
Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.
Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma
Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.
Immunotherapy Infuses New Hope Into Merkel Cell Carcinoma Care
While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.
FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Intralesional Combinations Pave the Way for Melanoma Treatment
The use of intralesional therapies in combination with checkpoint inhibitors has shown to be an improvement to monotherapy and combinations with immunotherapy in melanoma. 
Expert Addresses Ongoing Challenges in Melanoma
Merrick I. Ross, MD, discusses ongoing challenges in melanoma, including treating liver metastases, the diminished yet important role of surgery, and the need for better biomarkers.
Relatlimab/Nivolumab Combo Active in Melanoma After PD-1/PD-L1 Therapy
Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.
Avelumab Approved in Europe for Merkel Cell Carcinoma
The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.
Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma
The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.
FDA Accepts Filing for Binimetinib/Encorafenib Combo in BRAF+ Melanoma
The FDA has accepted new drug applications supporting use of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Publication Bottom Border
Border Publication